Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 354

1.

Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs.

Braucher DR, Henningson JN, Loving CL, Vincent AL, Kim E, Steitz J, Gambotto AA, Kehrli ME Jr.

Clin Vaccine Immunol. 2012 Nov;19(11):1722-9. doi: 10.1128/CVI.00315-12. Epub 2012 Aug 29.

2.

Influenza A virus hemagglutinin protein subunit vaccine elicits vaccine-associated enhanced respiratory disease in pigs.

Rajão DS, Loving CL, Gauger PC, Kitikoon P, Vincent AL.

Vaccine. 2014 Sep 8;32(40):5170-6. doi: 10.1016/j.vaccine.2014.07.059. Epub 2014 Jul 29.

PMID:
25077416
3.

Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.

Kim EH, Park HJ, Han GY, Song MK, Pereboev A, Hong JS, Chang J, Byun YH, Seong BL, Nguyen HH.

J Virol. 2014 Sep 1;88(17):9693-703. doi: 10.1128/JVI.00823-14. Epub 2014 Jun 11.

5.

Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs.

Thomas M, Wang Z, Sreenivasan CC, Hause BM, Gourapura J Renukaradhya, Li F, Francis DH, Kaushik RS, Khatri M.

Vaccine. 2015 Jan 15;33(4):542-8. doi: 10.1016/j.vaccine.2014.11.034. Epub 2014 Nov 28.

PMID:
25437101
6.

Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.

Klingbeil K, Lange E, Blohm U, Teifke JP, Mettenleiter TC, Fuchs W.

Virus Res. 2015 Mar 2;199:20-30. doi: 10.1016/j.virusres.2015.01.009. Epub 2015 Jan 17.

PMID:
25599604
7.

Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs.

Masic A, Lu X, Li J, Mutwiri GK, Babiuk LA, Brown EG, Zhou Y.

Vaccine. 2010 Oct 8;28(43):7098-108. doi: 10.1016/j.vaccine.2010.08.003. Epub 2010 Aug 12.

PMID:
20708697
8.

Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.

Ryder AB, Nachbagauer R, Buonocore L, Palese P, Krammer F, Rose JK.

J Virol. 2015 Dec 16;90(5):2544-50. doi: 10.1128/JVI.02598-15.

9.

Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC.

J Virol. 2014 Nov;88(22):13418-28. doi: 10.1128/JVI.01219-14. Epub 2014 Sep 10.

10.

Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.

Prabakaran M, Kolpe AB, He F, Kwang J.

Vaccine. 2013 Feb 27;31(10):1385-92. doi: 10.1016/j.vaccine.2013.01.003. Epub 2013 Jan 14.

PMID:
23328313
13.

Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.

Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP.

Vaccine. 2006 Feb 20;24(8):1180-90. Epub 2005 Sep 12.

PMID:
16194586
14.

Age at Vaccination and Timing of Infection Do Not Alter Vaccine-Associated Enhanced Respiratory Disease in Influenza A Virus-Infected Pigs.

Souza CK, Rajão DS, Loving CL, Gauger PC, Pérez DR, Vincent AL.

Clin Vaccine Immunol. 2016 Jun 6;23(6):470-82. doi: 10.1128/CVI.00563-15. Print 2016 Jun.

15.

Immune responses and protection efficacy of a recombinant swinepox virus expressing HA1 against swine H3N2 influenza virus in mice and pigs.

Xu J, Huang D, Liu S, Lin H, Zhu H, Liu B, Lu C.

Virus Res. 2012 Aug;167(2):188-95. doi: 10.1016/j.virusres.2012.04.014. Epub 2012 May 11.

PMID:
22584406
16.

Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.

Liu G, Song L, Reiserova L, Trivedi U, Li H, Liu X, Noah D, Hou F, Weaver B, Tussey L.

Vaccine. 2012 Nov 6;30(48):6833-8. doi: 10.1016/j.vaccine.2012.09.013. Epub 2012 Sep 18.

PMID:
23000130
17.

Cross-fostering to prevent maternal cell transfer did not prevent vaccine-associated enhanced respiratory disease that occurred following heterologous influenza challenge of pigs vaccinated in the presence of maternal immunity.

Loving CL, Brockmeier SL, Vincent AL, Gauger PC, Zanella EL, Lager KM, Kehrli ME Jr.

Viral Immunol. 2014 Sep;27(7):334-42. doi: 10.1089/vim.2014.0034. Epub 2014 Jun 30.

PMID:
24978861
18.

Live attenuated influenza A virus vaccine protects against A(H1N1)pdm09 heterologous challenge without vaccine associated enhanced respiratory disease.

Gauger PC, Loving CL, Khurana S, Lorusso A, Perez DR, Kehrli ME Jr, Roth JA, Golding H, Vincent AL.

Virology. 2014 Dec;471-473:93-104. doi: 10.1016/j.virol.2014.10.003. Epub 2014 Oct 28.

19.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
20.

Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.

Park KS, Seo YB, Lee JY, Im SJ, Seo SH, Song MS, Choi YK, Sung YC.

Vaccine. 2011 Jul 26;29(33):5481-7. doi: 10.1016/j.vaccine.2011.05.062. Epub 2011 Jun 12.

PMID:
21664216

Supplemental Content

Support Center